ARWRNasdaqPharmaceutical PreparationsFiscal year ends September 30
ARROWHEAD PHARMACEUTICALS, INC.
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$57.23+1.33 (+2.38%)
Close on Oct 19, 2026
- Market cap
- $8.21B
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
84.6%
120M of 141M shares
Institutional holders
499
126 new, 58 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
0 buys · 64 sales
Net sold $37.34M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| FMR LLC | 7,349,107 | 5.20% | 13G (passive) | Mar 31, 2026 |
| Vanguard Capital Management | 7,081,293 | 5.05% | 13G (passive) | Mar 31, 2026 |
| BlackRock, Inc. | 14,232,545 | 10.10% | 13G (passive) amendment | Jun 30, 2026 |
| Avoro Capital Advisors LLC | 13,823,383 | 9.64% | 13G (passive) amendment | Jun 30, 2026 |
| Sarepta Therapeutics Investments, Inc. | 11,926,301 | 9.50% | 13D (active) | Feb 7, 2025 |
| Behzad Aghazadeh | 11,517,441 | 8.30% | 13G (passive) amendment | Jun 30, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ARWR | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 14,830,553 | 10.50% | $1.21B | −3,330,966 | 0.02% |
| Avoro Capital Advisors LLC | 11,355,555 | 8.04% | $925.59M | +655,556 | 8.31% |
| FMR LLC | 8,039,804 | 5.69% | $655.32M | +773,152 | 0.03% |
| Vanguard Portfolio Management LLC | 6,351,355 | 4.50% | $517.70M | −794,781 | 0.02% |
| Vanguard Capital Management LLC | 6,110,953 | 4.33% | $498.10M | +78,537 | 0.01% |
| State Street Corp | 5,694,640 | 4.03% | $464.17M | −801,490 | 0.01% |
| Norges Bank | 3,896,536 | 2.76% | $317.61M | New | 0.03% |
| Invesco Ltd. | 3,883,976 | 2.75% | $316.58M | +603,329 | 0.03% |
| Geode Capital Management, LLC | 3,530,612 | 2.50% | $298.81M | −748,216 | 0.02% |
| Fred Alger Management, LLC | 3,301,919 | 2.34% | $269.14M | −40,574 | 0.90% |
| Baker Bros. Advisors LP | 1,992,783 | 1.41% | $162.43M | – | 0.81% |
| Siren, L.L.C. | 1,715,476 | 1.21% | $139.83M | +100,000 | 2.83% |
| Vestal Point Capital, LP | 1,575,000 | 1.12% | $128.38M | −700,000 | 3.00% |
| Deerfield Management Company, L.P. (Series C) | 1,389,055 | 0.98% | $113.22M | −184,242 | 1.18% |
| First Trust Advisors LP | 1,352,918 | 0.96% | $110.28M | +1,203,770 | 0.06% |
| Driehaus Capital Management LLC | 1,350,556 | 0.96% | $110.08M | +160,221 | 0.64% |
| Jupiter Topco LLC | 1,221,596 | 0.86% | $99.62M | New | 0.04% |
| Northern Trust Corp | 1,192,868 | 0.84% | $97.23M | −462,969 | 0.01% |
| Dimensional Fund Advisors LP | 1,181,608 | 0.84% | $96.31M | +573,077 | 0.02% |
| Goldman Sachs Group Inc | 1,150,007 | 0.81% | $93.74M | −589,916 | 0.01% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 499 | 120M | 84.6% | 126 / 153 | 157 / 58 | 18M | 18M |
| Q1 2026 | 437 | 121M | 85.5% | 106 / 171 | 112 / 62 | 36M | 16M |
| Q4 2025 | 401 | 116M | 82.1% | 127 / 125 | 110 / 27 | 17M | 13M |
| Q3 2025 | 303 | 112M | 79.1% | 66 / 101 | 82 / 41 | 17M | 11M |
| Q2 2025 | 281 | 106M | 75.2% | 57 / 97 | 82 / 38 | 13M | 12M |
| Q1 2025 | 264 | 105M | 74.5% | 43 / 89 | 81 / 47 | 17M | 11M |
| Q4 2024 | 270 | 100M | 70.6% | 44 / 93 | 85 / 42 | 9M | 10M |
| Q3 2024 | 272 | 100M | 70.8% | 34 / 92 | 90 / 32 | 26M | 11M |
| Q2 2024 | 272 | 100M | 70.8% | 34 / 97 | 87 / 34 | 9M | 9M |
| Q1 2024 | 273 | 102M | 72.0% | 40 / 107 | 75 / 30 | 29M | 9M |
| Q4 2023 | 266 | 81M | 57.5% | 44 / 77 | 96 / 34 | 13M | 7M |
| Q3 2023 | 256 | 75M | 53.0% | 21 / 91 | 96 / 38 | 7M | 5M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of ARWR | Value | % of fund | As of |
|---|---|---|---|---|---|
| iShares Core S&P Mid-Cap ETF | 4,820,474 | 3.41% | $392.92M | 0.32% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 4,246,637 | 3.01% | $346.14M | 0.02% | Jun 30, 2026 |
| Vanguard Small-Cap Index Fund | 3,067,819 | 2.17% | $250.06M | 0.13% | Jun 30, 2026 |
| Fidelity Growth Company Fund | 2,362,371 | 1.67% | $184.05M | 0.19% | May 31, 2026 |
| Vanguard Small-Cap Growth Index Fund | 1,768,635 | 1.25% | $144.16M | 0.31% | Jun 30, 2026 |
| Invesco S&P MidCap Momentum ETF | 1,736,475 | 1.23% | $146.99M | 2.05% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 1,614,924 | 1.14% | $131.63M | 0.13% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 1,407,587 | 1.00% | $114.73M | 1.07% | Jun 30, 2026 |
| First Trust NYSE Arca Biotechnology Index Fund | 1,165,127 | 0.82% | $94.97M | 3.38% | Jun 30, 2026 |
| iShares Biotechnology ETF | 937,699 | 0.66% | $76.43M | 0.84% | Jun 30, 2026 |
| iShares S&P Mid-Cap 400 Growth ETF | 842,687 | 0.60% | $68.69M | 0.61% | Jun 30, 2026 |
| Alger Focus Equity Fund | 762,514 | 0.54% | $64.55M | 0.91% | Jul 31, 2026 |
| Fidelity Extended Market Index Fund | 720,889 | 0.51% | $56.16M | 0.13% | May 31, 2026 |
| State Street(R) SPDR(R) Portfolio S&P 400(TM) Mid Cap ETF | 712,985 | 0.50% | $58.12M | 0.32% | Jun 30, 2026 |
| Vanguard Russell 2000 Index Fund | 694,990 | 0.49% | $54.15M | 0.31% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Christopher Richard Anzalone | Chief Executive Officer, Director | 3,798,510 | 2.69% | Jan 5, 2026 |
| Daniel Joseph Apel | Chief Financial Officer | 172,792 | 0.12% | Apr 24, 2026 |
| James C. Hamilton | Chief Medical Officer | 226,958 | 0.16% | Apr 24, 2026 |
| Patrick O'Brien | COO | 472,848 | 0.33% | Jan 8, 2026 |
| Kenneth Allen Myszkowski | Chief Financial Officer | 465,433 | 0.33% | Jan 7, 2025 |
| Adeoye Y. Olukotun | Director | 31,600 | 0.02% | Aug 20, 2026 |
| Michael S. Perry | Director | 111,459 | 0.08% | Aug 20, 2026 |
| Matthew Gregory Cohen | Director | 11,882 | 0.01% | Jun 17, 2026 |
| Hongbo Lu | Director | 57,662 | 0.04% | May 14, 2026 |
| Mauro Ferrari | Director | 69,053 | 0.05% | Dec 30, 2025 |
| William D. Waddill | Director | 56,563 | 0.04% | Dec 23, 2025 |
| Victoria Vakiener | Director | 37,683 | 0.03% | Dec 23, 2025 |
| Douglas S. Ingram | Director | 46,215 | 0.03% | Dec 18, 2025 |
| Douglas B. Given | Director | 136,667 | 0.10% | Dec 18, 2024 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Michael S. Perry Director | Aug 18, 2026 | Sale | −11,600 | $87.30 | $1.01M | 111,459 |
| Adeoye Y. Olukotun Director | Aug 18, 2026 | Sale | −2,000 | $86.96 | $173.92K | 31,600 |
| Matthew Gregory Cohen Director | Jun 15, 2026 | Award | +11,882 | – | – | 11,882 |
| Hongbo Lu Director | May 12, 2026 | Sale(10b5-1 plan) | −2,970 | $76.88 | $228.33K | 52,012 |
| James C. Hamilton Chief Medical Officer | Apr 23, 2026 | Sale(10b5-1 plan) | −10,000 | $75.00 | $750.00K | 226,958 |
| Daniel Joseph Apel Chief Financial Officer | Apr 22, 2026 | Sale(10b5-1 plan) | −3,208 | $70.11 | $224.91K | 172,792 |
| Daniel Joseph Apel Chief Financial Officer | Apr 22, 2026 | Sale(10b5-1 plan) | −1,157 | $70.45 | $81.51K | 171,635 |
| Daniel Joseph Apel Chief Financial Officer | Apr 22, 2026 | Sale(10b5-1 plan) | −8,730 | $71.92 | $627.86K | 162,905 |
| James C. Hamilton Chief Medical Officer | Mar 5, 2026 | Sale(10b5-1 plan) | −10,000 | $64.19 | $641.90K | 236,958 |
| Patrick O'Brien COO | Jan 6, 2026 | Gift | −440 | – | – | 472,848 |
| Patrick O'Brien COO | Jan 6, 2026 | Gift | −540 | – | – | 474,368 |
| Patrick O'Brien COO | Jan 6, 2026 | Gift | −540 | – | – | 473,828 |
| Patrick O'Brien COO | Jan 6, 2026 | Gift | −440 | – | – | 472,408 |
| Patrick O'Brien COO | Jan 6, 2026 | Award | +75,000 | – | – | 547,408 |
| Patrick O'Brien COO | Jan 6, 2026 | Gift | −540 | – | – | 473,288 |
| Daniel Joseph Apel Chief Financial Officer | Jan 6, 2026 | Award | +75,000 | – | – | 176,200 |
| James C. Hamilton Chief Medical Officer | Jan 6, 2026 | Award | +75,000 | – | – | 246,958 |
| James C. Hamilton Chief Medical Officer | Jan 5, 2026 | Sale(10b5-1 plan) | −12,711 | $63.95 | $812.87K | 173,904 |
| James C. Hamilton Chief Medical Officer | Jan 5, 2026 | Sale(10b5-1 plan) | −437 | $65.97 | $28.83K | 172,267 |
| James C. Hamilton Chief Medical Officer | Jan 5, 2026 | Sale(10b5-1 plan) | −1,200 | $64.49 | $77.39K | 172,704 |
| James C. Hamilton Chief Medical Officer | Jan 5, 2026 | Sale(10b5-1 plan) | −309 | $68.00 | $21.01K | 171,958 |
| James C. Hamilton Chief Medical Officer | Jan 5, 2026 | Sale(10b5-1 plan) | −14,792 | $63.01 | $932.04K | 186,615 |
| James C. Hamilton Chief Medical Officer | Jan 5, 2026 | Sale(10b5-1 plan) | −6,090 | $62.28 | $379.29K | 201,407 |
| James C. Hamilton Chief Medical Officer | Jan 5, 2026 | Sale(10b5-1 plan) | −4,625 | $61.24 | $283.24K | 207,497 |
| Patrick O'Brien COO | Jan 5, 2026 | Sale(10b5-1 plan) | −2,336 | $64.04 | $149.60K | 474,954 |
| Patrick O'Brien COO | Jan 5, 2026 | Sale(10b5-1 plan) | −5,873 | $62.91 | $369.47K | 477,290 |
| Patrick O'Brien COO | Jan 5, 2026 | Sale(10b5-1 plan) | −900 | $62.25 | $56.03K | 483,163 |
| Patrick O'Brien COO | Jan 5, 2026 | Sale(10b5-1 plan) | −600 | $61.12 | $36.67K | 484,063 |
| Patrick O'Brien COO | Jan 5, 2026 | Sale(10b5-1 plan) | −313 | $68.00 | $21.28K | 484,663 |
| Patrick O'Brien COO | Jan 5, 2026 | Sale(10b5-1 plan) | −900 | $66.01 | $59.41K | 484,976 |
| Patrick O'Brien COO | Jan 5, 2026 | Sale(10b5-1 plan) | −2,700 | $64.44 | $173.99K | 485,876 |
| Patrick O'Brien COO | Jan 5, 2026 | Sale(10b5-1 plan) | −11,842 | $63.84 | $755.99K | 488,576 |
| Patrick O'Brien COO | Jan 5, 2026 | Sale(10b5-1 plan) | −13,451 | $62.96 | $846.87K | 500,418 |
| Patrick O'Brien COO | Jan 5, 2026 | Sale(10b5-1 plan) | −6,164 | $62.23 | $383.59K | 513,869 |
| Patrick O'Brien COO | Jan 5, 2026 | Sale(10b5-1 plan) | −4,368 | $61.20 | $267.32K | 520,033 |
| Patrick O'Brien COO | Jan 5, 2026 | Sale(10b5-1 plan) | −46 | $68.00 | $3.13K | 474,908 |
| Christopher Richard Anzalone Chief Executive Officer, Director | Jan 2, 2026 | Sale(10b5-1 plan) | −7,416 | $65.88 | $488.57K | 3,798,510 |
| Christopher Richard Anzalone Chief Executive Officer, Director | Jan 2, 2026 | Sale(10b5-1 plan) | −5,771 | $66.39 | $383.14K | 3,792,739 |
| Patrick O'Brien COO | Dec 31, 2025 | Gift | −560 | – | – | 526,081 |
| Patrick O'Brien COO | Dec 31, 2025 | Gift | −560 | – | – | 524,401 |
| Patrick O'Brien COO | Dec 31, 2025 | Gift | −560 | – | – | 524,961 |
| Patrick O'Brien COO | Dec 31, 2025 | Gift | −560 | – | – | 525,521 |
| Patrick O'Brien COO | Dec 31, 2025 | Gift | −560 | – | – | 526,641 |
| Christopher Richard Anzalone Chief Executive Officer, Director | Dec 29, 2025 | Option exercise | +35,181 | $6.15 | $216.36K | 3,841,107 |
| Christopher Richard Anzalone Chief Executive Officer, Director | Dec 29, 2025 | Option exercise | +16,545 | $6.15 | $101.75K | 3,857,652 |
| Christopher Richard Anzalone Chief Executive Officer, Director | Dec 29, 2025 | Sale(10b5-1 plan) | −35,181 | $69.33 | $2.44M | 3,822,471 |
| Christopher Richard Anzalone Chief Executive Officer, Director | Dec 29, 2025 | Sale(10b5-1 plan) | −16,545 | $68.69 | $1.14M | 3,805,926 |
| Mauro Ferrari Director | Dec 26, 2025 | Sale(10b5-1 plan) | −7,530 | $70.00 | $527.10K | 69,053 |
| Christopher Richard Anzalone Chief Executive Officer, Director | Dec 22, 2025 | Sale(10b5-1 plan) | −10,012 | $68.33 | $684.12K | 3,808,500 |
| Christopher Richard Anzalone Chief Executive Officer, Director | Dec 22, 2025 | Sale(10b5-1 plan) | −2,574 | $68.85 | $177.22K | 3,805,926 |
| Adeoye Y. Olukotun Director | Dec 19, 2025 | Sale(10b5-1 plan) | −827 | $68.48 | $56.63K | 33,600 |
| Adeoye Y. Olukotun Director | Dec 19, 2025 | Sale(10b5-1 plan) | −6,083 | $68.04 | $413.89K | 34,427 |
| Adeoye Y. Olukotun Director | Dec 19, 2025 | Sale(10b5-1 plan) | −3,090 | $66.70 | $206.10K | 40,510 |
| William D. Waddill Director | Dec 19, 2025 | Sale(10b5-1 plan) | −500 | $68.53 | $34.27K | 56,563 |
| William D. Waddill Director | Dec 19, 2025 | Sale(10b5-1 plan) | −2,416 | $66.66 | $161.05K | 62,514 |
| William D. Waddill Director | Dec 19, 2025 | Sale(10b5-1 plan) | −5,451 | $68.01 | $370.72K | 57,063 |
| Christopher Richard Anzalone Chief Executive Officer, Director | Dec 19, 2025 | Sale(10b5-1 plan) | −1,319 | $68.48 | $90.33K | 3,818,512 |
| Christopher Richard Anzalone Chief Executive Officer, Director | Dec 19, 2025 | Sale(10b5-1 plan) | −8,147 | $68.01 | $554.08K | 3,819,831 |
| Christopher Richard Anzalone Chief Executive Officer, Director | Dec 19, 2025 | Sale(10b5-1 plan) | −3,979 | $66.67 | $265.28K | 3,827,978 |
| Victoria Vakiener Director | Dec 19, 2025 | Sale(10b5-1 plan) | −5,281 | $67.97 | $358.95K | 37,683 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Perry Michael Director | Aug 18, 2026 | 11,600 | $1.01M | Aug 18, 2026 | Compensation |
| Olukotun Adeoye Director | Aug 18, 2026 | 2,000 | $173.88K | Aug 18, 2026 | Compensation |
| Apel Daniel Officer | May 19, 2026 | 13,095 | $934.21K | Apr 22, 2026 | Bonus |
| Lu Hongbo Officer | May 19, 2026 | 2,970 | $228.30K | May 12, 2026 | Compensation |
| Hamilton James Officer | May 19, 2026 | 10,000 | $750.00K | Apr 23, 2026 | Compensation |
| Lu Hongbo Officer | May 12, 2026 | 2,970 | $228.30K | May 12, 2026 | Compensation |
| Hamilton James Officer | Apr 23, 2026 | 10,000 | $750.00K | Apr 23, 2026 | Compensation |
| Apel Daniel Officer | Apr 22, 2026 | 13,095 | $934.21K | Apr 22, 2026 | Bonus |
| Hamilton James Officer | Mar 5, 2026 | 10,000 | $641.87K | Mar 5, 2026 | Compensation |
| O'Brien Patrick Officer | Jan 5, 2026 | 49,493 | $3.12M | Jan 5, 2026 | Compensation |
| Hamilton James Officer | Jan 5, 2026 | 39,728 | $2.51M | Jan 5, 2026 | Compensation |
| Hamilton James Officer | Jan 5, 2026 | 40,164 | $2.53M | Jan 5, 2026 | Compensation |
| Anzalone Christopher Officer | Jan 2, 2026 | 13,187 | $871.67K | Jan 2, 2026 | Compensation |
| Anzalone Christopher Officer | Dec 29, 2025 | 51,726 | $3.58M | Dec 29, 2025 | Compensation |
| Ferrari Mauro Director | Dec 29, 2025 | 7,530 | $527.07K | Dec 26, 2025 | Compensation |